Rational small molecule drug discovery and development requires a clear line of sight between biology, chemistry and clinical application. CellCentric’s CCS1477 programme targets specific gene and protein regulatory mechanisms of action with a highly potent, selective small molecule inhibitor. In their latest blog, CellCentric describe how this then translates to specific applications in cancer, addressing significant clinical unmet needs.

Read the full blog here.